Phase ii study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Urologic Neoplasms
  • Urothelium

abstract

  • The 95% one-sided lower confidence bound of 4.77 months for median PFS did not meet the predesignated PFS of more than 4.8 months considered sufficient for further study. Median OS was greater than expected. An ongoing phase III trial in patients who are eligible for therapy with cisplatin will define the role of bevacizumab in UC.

publication date

  • February 20, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3574268

Digital Object Identifier (DOI)

  • 10.1200/JCO.2012.42.5215

PubMed ID

  • 23341513

Additional Document Info

start page

  • 724

end page

  • 30

volume

  • 31

number

  • 6